Molecular and Cellular Determinants of Human Iron Overload Cardiomyopathy

Sayli S Modak1,2, Lina Greenberg1, W Tom Stump1

  • 1Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, 63110, USA.

Insights

Iron overload cardiomyopathy (IOC) damages heart function by affecting calcium transients and sarcomeric proteins. New engineered heart tissues model IOC, revealing iron

Area of Science:

  • Cardiovascular Biology
  • Stem Cell Technology
  • Biomaterials Science

Background:

  • Iron overload cardiomyopathy (IOC) results from excess systemic iron, causing cardiac dysfunction and arrhythmias.
  • Studying IOC's cardiac-specific mechanisms is challenging due to multi-organ involvement.
  • Existing models struggle to replicate the complex contractile and electrical aspects of IOC.

Purpose of the Study:

  • To develop and utilize in vitro models to investigate the cellular and molecular mechanisms of human IOC.
  • To probe the impact of iron overload on engineered human heart tissues.
  • To identify specific pathways contributing to cardiac dysfunction in IOC.

Main Methods:

  • Human engineered heart tissues (EHTs) composed of cardiomyocytes and cardiac fibroblasts were created.
  • EHTs were subjected to iron overload conditions to mimic IOC.
  • Cellular viability, reactive oxygen species (ROS) production, action potentials, calcium transients, and contractile force were assessed.

Main Results:

  • Engineered heart tissues recapitulated key IOC features: reduced systolic/diastolic function and arrhythmias.
  • Both cell types accumulated iron, but cardiomyocytes showed higher iron and ROS levels.
  • Iron overload impaired calcium transient kinetics and amplitude, impacting contractility through oxidative damage and myosin inhibition.

Conclusions:

  • Engineered heart tissues provide a faithful in vitro model for studying human IOC.
  • Iron overload directly impairs cardiomyocyte calcium handling and contractile protein function.
  • This research elucidates novel cellular and molecular mechanisms underlying IOC pathogenesis.

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
589
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
526
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
587
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
470
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
619
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
365